Enhanced Goes Public at $1.2 Billion Ahead of Drug-Friendly Games
Enhanced CEO Maximilian Martin told Bloomberg Technology that the newly public company is trying to build a sports and consumer-products business around open, medically supervised performance enhancement. Fresh from a SPAC merger that valued Enhanced at $1.2bn, Martin argued that the Enhanced Games and its related “Live Enhanced” platform should let fans, customers and retail investors own part of what he called a movement. His central claim is that the model is not illicit “Olympics on steroids,” but enhancement using FDA-approved substances under doctor supervision and repeated medical screening.
Enhanced is selling ownership in the movement, not just tickets or products
Maximilian Martin says Enhanced went public because the company sees itself as “a movement” and wants its audience to have a financial stake in it. The company is building around the Enhanced Games, an Olympics-style sports event in which Martin says athletes may take FDA-approved substances under doctor supervision, and around a consumer-facing “Live Enhanced” platform for enhancement products. His argument is that spectators and customers should not only watch the competitions or buy longevity-related products, but also “own a piece of it.”
The listing came through a merger with a blank-check company, a SPAC deal that valued Enhanced at $1.2 billion. A market graphic identified Enhanced Group Inc. as beginning New York Stock Exchange trading following the Paradise Acquisition transaction, with intraday data at 8.74, up 0.71, or 8.84%.
Martin framed the listing as especially relevant to retail investors. Sports, he said, has traditionally been less accessible as an investment category for retail than for institutional players. Enhanced, in his view, changes that by putting a sports and enhancement-products company on a public exchange.
Enhanced as a stock opportunity is really for everyone, but I think particularly exciting for retail too.
Caroline Hyde pressed whether this was, in effect, a retail investment play: the same people who might buy peptides or other longevity products through Enhanced’s platform, and who might attend or watch the Enhanced Games, could also buy the company’s stock. Martin agreed that retail investors are a particular focus, while still presenting the opportunity as broadly available.
The central dispute is whether “Olympics on steroids” misdescribes the model
Caroline Hyde put the reputational problem plainly: prior media attention has described the Games as “Olympics on steroids.” Martin rejected that phrase, not because Enhanced denies that performance enhancement is central to the model, but because he says “steroids” carries the wrong legal and cultural associations.
His distinction is between illicit or hidden drug use and a medically supervised framework. According to Martin, athletes at the Enhanced Games may take FDA-approved substances under doctor supervision. He said athletes also must pass medical screenings over time, regardless of whether they choose to enhance, to determine whether they are healthy and safe to compete.
That is the line Martin wants investors, viewers, and customers to understand. The company is not presenting enhancement as a secretive workaround to sports regulation. It is presenting enhancement as open, supervised, and embedded in a health-and-safety protocol.
Steroids is really for people thinking about happening in the garage in the backdoor locker room of a gym, etc. But that's not it. This is out all in the open.
Martin’s language does important work here. He did not say the Games are free of enhancement. He said the enhancement is medically regulated, limited to FDA-approved substances, and paired with repeated screening. His claim is that openness and doctor supervision make the system safer for athletes and, by extension, for consumers using products offered through Enhanced.
A company presentation visual, credited to Enhanced Games, depicted a large stadium complex with a transparent dome and “E+” branding. Additional footage showed a man in a gym being tracked by a 3D movement model, a trainer examining an athlete’s shoulder mobility, a swimmer in an indoor pool, and a heavy barbell snatch. Those images sat alongside Martin’s attempt to separate Enhanced’s model from the “garage” or “backdoor locker room” associations he attached to steroids.
The investment pitch bundles spectacle, products, and public equity
A backer graphic listed Peter Thiel, former Coinbase CTO Balaji Srinivasan, Apeiron Investment Group, and 1789 Capital under the heading “NOTEABLE BACKERS OF ENHANCED.” That capital backdrop matters because Martin’s pitch was not confined to staging a sports event. He described a broader structure in which supporters can watch the Games, buy enhancement products through Live Enhanced, and now own listed shares.
One inference from Martin’s watch-buy-own framing is that those forms of participation could overlap. A person attracted to the Games may also be the kind of consumer interested in longevity or enhancement products. A person who buys those products may also be receptive to owning the company’s stock. Martin did not lay out that mechanism in detail; he argued more simply that going public lets the people in the movement own a piece of it.
The unresolved tension is the same one Hyde raised through the “Olympics on steroids” shorthand. Enhanced wants the public market to treat the company as a legitimate sports and enhancement business. Its differentiator, however, is precisely that it allows enhancement under defined conditions. Martin’s answer is that legality, FDA approval, doctor supervision, and screening separate the Enhanced Games from the negative associations attached to steroids. Whether that distinction is persuasive is the question the listing now exposes to retail investors as well as institutions.